• +1-646-491-9876
    • +91-20-67278686

    Search

    Lung Transplant Rejection Pipeline Review H1 2017

    Lung Transplant Rejection Pipeline Review H1 2017

    • Report Code ID: RW0001799269
    • Category Pharmaceuticals
    • No. of Pages 65
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Lung Transplant Rejection - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Lung Transplant Rejection - Pipeline Review, H1 2017, provides an overview of the Lung Transplant Rejection (Immunology) pipeline landscape.

    Lung transplantation is the therapy used in various lung diseases. Lung transplant replaces an injured or diseased lung with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted lung as foreign and may work against it. Patients may hence develop complications and eventually reject the new organ. Immunosuppressive drugs are administered simultaneously which prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Lung Transplant Rejection - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Lung Transplant Rejection (Immunology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Lung Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Lung Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 4 and 1 respectively.

    Lung Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Lung Transplant Rejection (Immunology) .
    - The pipeline guide reviews pipeline therapeutics for Lung Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Lung Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Lung Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Lung Transplant Rejection (Immunology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Lung Transplant Rejection (Immunology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Lung Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Lung Transplant Rejection - Overview
    Lung Transplant Rejection - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Lung Transplant Rejection - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Lung Transplant Rejection - Companies Involved in Therapeutics Development
    Dompe Farmaceutici SpA
    Kamada Ltd
    Novartis AG
    Quark Pharmaceuticals Inc
    Lung Transplant Rejection - Drug Profiles
    alpha-1 proteinase inhibitor (human) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    everolimus - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FX-06 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    QPI-1024 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    QPLI-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    R-554 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    R-801 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    reparixin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    solnatide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tiprelestat - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Lung Transplant Rejection - Dormant Projects
    Lung Transplant Rejection - Product Development Milestones
    Featured News & Press Releases
    Apr 06, 2016: Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection
    Dec 09, 2015: Quark announces issue of U.S. patent for novel treatment of lung transplantation associated injury
    Jun 22, 2015: Kamada Collaborates with Baxalta on Phase 1/2 Clinical Trial with Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection
    Mar 12, 2015: Elafin combined with cyclosporine promises to overcome limitations of cyclosporine for preventing irreversible damage to transplanted organs
    Apr 17, 2013: APEPTICO initiates phase II clinical trial with AP301 in patients with primary graft dysfunction following lung transplantation
    Dec 06, 2011: Proteo And Its Subsidiary Announce Major Advances In Elafin Development Program
    Sep 08, 2009: APEPTICO Presents Lead Product AP301 At Annual Congress Of European Respiratory Society In Vienna, Austria
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Lung Transplant Rejection, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Lung Transplant Rejection - Pipeline by Apeptico Forschung und Entwicklung GmbH, H1 2017
    Lung Transplant Rejection - Pipeline by Dompe Farmaceutici SpA, H1 2017
    Lung Transplant Rejection - Pipeline by Kamada Ltd, H1 2017
    Lung Transplant Rejection - Pipeline by Novartis AG, H1 2017
    Lung Transplant Rejection - Pipeline by Quark Pharmaceuticals Inc, H1 2017
    Lung Transplant Rejection - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Lung Transplant Rejection, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Dompe Farmaceutici SpA
    Kamada Ltd
    Novartis AG
    Quark Pharmaceuticals Inc

    Request for Sample

    Report Url http://www.reportsweb.com//lung-transplant-rejection-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//lung-transplant-rejection-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//lung-transplant-rejection-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments